clinical trial · NCT07156253
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd·phase1·recruiting·n = 110
Metastatic Solid TumorOvarian CancerBreast CancerBRCA 1 /2 and / or HRDAdvanced Solid TumorsSYN818 and Olaparib will be administered
brief summary
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors
started
Aug 26, 2025
primary completion
Aug 25, 2028
completion
Feb 25, 2029
last updated
Sep 5, 2025
detailed description
This study is a Phase Ib, open-label, multicentre study of SYN818 with Olaparib administered orally in patients with locally advanced or metastatic solid tumors harboring mutations in BRCA and/or defects in the homologous recombination repair (HRR) pathway
official title
A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYN818 With Olaparib in Patients With Locally Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol